HMOs update: FSANZ approves dsm-firmenich’s 2’-FL and three other HMOs for use in infant formulas

By Tingmin Koe

- Last updated on GMT

dsm-firmenich has received approval for supplying HMOs 2'-FL, LNT, 6'-SL sodium salt, and 3'-SL sodium salt for use in infant formulas in Australia and New Zealand. ©Getty Images
dsm-firmenich has received approval for supplying HMOs 2'-FL, LNT, 6'-SL sodium salt, and 3'-SL sodium salt for use in infant formulas in Australia and New Zealand. ©Getty Images

Related tags DSM-Firmenich HMOs human milk oligosaccharides 2'-fucosyllactose Fsanz

Food Standards Australia New Zealand (FSANZ) has approved dsm-firmenich’s four human milk oligosaccharides (HMOs), including the mixture of 2’-fucosyllactose (2’-FL) and difucosyllactose (DFL), for use in infant formula products.

The approval allows 2’-FL/DFL to be added in infant formulas up to a maximum limit of 96mg/100 kJ.

The other three HMOs approved are lacto-N-tetraose (LNT), 6’-sialyllactose (6’-SL) sodium salt, and 3’-siallylactose (3’-SL) sodium salt, with a maximum limit of 32mg/100kJ, 16mg/100kJ, and 8mg/100 kJ respectively. 

These HMOs are produced by the company’s subsidiary firm Glycom A/S and marketed under the trademark GlyCareTM​.

The approval also granted dsm-firmenich exclusivity in supplying the four HMOs for infant formula use in Australia and New Zealand for 15 months from the date of gazettal.

These four HMOs are produced by microbial fermentation using a genetically modified strain of Escherichia coli ​K-12.

Dsm-firmenich said that it was the first HMO manufacturer to apply and obtain approval for the four HMOs in the region.

We were the first company to bring 2’-fucosyllactose (2’-FL) and lacto-N-neotetraose (LNnT) HMOs to Australia and New Zealand. But the approval of these additional four ingredients opens up even more avenues for pioneering advancements in the realm of early life nutrition,” ​said Christoph Röhrig, head of HMO Regulatory.

The company also believes that the approval would support its HMOs market access in other APAC countries.

“Australia and New Zealand are important markets as FSANZ opinions are highly valued by regulatory authorities in other countries - particularly in Asia-Pacific - and therefore support market access to these HMOs in other regions”, ​said Maryse Darch, regulatory and scientific affairs manager.

Elsewhere in Singapore, Thailand, EU, and the US, the company has also received approval for the use of its six HMOs, namely 2’-FL, 2’-FL/DFL, LNT, 6’-SL sodium salt, 3’-SL sodium salt, and Lacto-N-neotetraose (LNnT).

The FSANZ, on the other hand, said in its risk assessment report, that the inclusion of a wide range of HMOs to infant formulas have could enable the microbiota profile of formula-fed babies to more closely resemble that of breastfed infants.

It pointed out that evidence has shown that HMOs added to infant formulas could lead to an increase in the abundance of Bifidobacterium spp ​in infant gut microbiota, citing findings from a 2022 study by Bosheva et al​.

According to the study, there was a significant increase especially for Bifidobacterium longum subsp. Infantis(B. infantis)​, in infants who consumed infant formulas containing 1.5 g/L of HMOs – including 2’-FL, LNT, 3’-SL, 6’-SL – as compared to the control group. Their gut microbiota was also more similar to the breastfed group.

The study also showed the anti-pathogenic effects of the HiMO blend through a significant reduction in Clostridioides difficle​, a bacterium that causes diarrhoea and colon inflammation or colitis.

On the other hand, 2′-FL was also shown to support inflammatory suppression and facilitate appropriate immune responses and antigenic memory, the FSANZ said.

Other companies that have secured HMOs approval from FSANZ previously included Friesland Campina​, whose 2’-FL trademarked AequivalTM​ was approved for a 15-month exclusive use in October 2022.

Related news

Show more

Related products

show more

New digestive wellness solution with clinical evidence

New digestive wellness solution with clinical evidence

Content provided by Symrise AG | 31-May-2024 | Product Brochure

16% of adults across the globe are suffering from constipation¹. Functional gastrointestinal disorders are a worldwide issue, impacting the life of 15,2%...

ABKEFIR™: New Edge in Probiotics & Postbiotics

ABKEFIR™: New Edge in Probiotics & Postbiotics

Content provided by SYNBIO TECH INC. | 08-May-2024 | Product Brochure

Kefir, originating from the Caucasus region, is a traditional fermented beverage known for its rich probiotic and probiotic metabolites. It has become...

Harness the power of algae for omega-3 innovation

Harness the power of algae for omega-3 innovation

Content provided by dsm-firmenich | 08-May-2024 | Insight Guide

Algal-sourced omega-3s have limitless potential, able to scale to meet the needs of our planet’s population with twice the potency – naturally – and all...

Related suppliers

Follow us


View more


Nutra Champions Podcast

Nutra Champions Podcast